Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORT1 | Q99523 | 12/20 | 1.00 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15903272 | 0.95 | SORT1 (0.90) | SORT1NAMPTSMN1; SMN2GSK3BMMP13 | |
| SCHEMBL15903335 | 0.85 | SORT1 (1.00) | SORT1NAMPTSMN1; SMN2MMP13 | |
| SCHEMBL15903416 | 0.83 | SORT1 (0.71) | SORT1NAMPTSMN1; SMN2GSK3BMAPK1 | |
| SCHEMBL15903418 | 0.81 | SORT1 (0.68) | SORT1NAMPTSMN1; SMN2GSK3BMAPK1 | |
| SCHEMBL15903338 | 0.81 | SORT1 (0.91) | SORT1NAMPTSMN1; SMN2MMP13 | |
| SCHEMBL11628816 | 0.81 | NAMPT (0.67) | SORT1NAMPTSMN1; SMN2GSK3BMMP13 | |
| SCHEMBL55687 | 0.80 | SORT1 (0.66) | SORT1 | |
| Hydrochloric Acid SCHEMBL11627973 | 0.79 | SORT1 (0.65) | SORT1NAMPTSMN1; SMN2GSK3BMMP13 | |
| SCHEMBL15903132 | 0.79 | SORT1 (1.00) | SORT1HSD17B10 | |
| SCHEMBL6160362 | 0.78 | KMT2A (0.78) | SORT1SMN1; SMN2GSK3BMMP13MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948147-B1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H LUNDBECK AS (DK) | 2019-03-13 | — | — | EP | claimed |
| US-10195186-B2 | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | H. LUNDBECK A/S (DK) | 2019-02-05 | — | — | US | claimed |
| US-20170239226-A1 | N-Substituted-5-Substituted Phthalamic Acids as Sortilin Inhibitors | H. LUNDBECK A/S (DK) | 2017-08-24 | — | — | US | claimed |
| US-9682967-B2 | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | H. LUNDBECK A/S (DK) | 2017-06-20 | — | — | US | claimed |
| US-20150368231-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H. LUNDBECK A/S (DK) | 2015-12-24 | — | — | US | claimed |
| EP-2948147-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H. Lundbeck A/S (DK) | 2015-12-02 | — | — | EP | claimed |
| WO-2014114779-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H. LUNDBECK A/S (DK) | 2014-07-31 | — | — | WO | claimed |
| EP-2948147-B1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H LUNDBECK AS (DK) | 2019-03-13 | — | — | EP | disclosed |
| EP-2948147-B1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H LUNDBECK AS (DK) | 2019-03-13 | — | — | EP | disclosed |
| US-10195186-B2 | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | H. LUNDBECK A/S (DK) | 2019-02-05 | — | — | US | disclosed |
| US-10195186-B2 | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | H. LUNDBECK A/S (DK) | 2019-02-05 | — | — | US | disclosed |
| US-20170239226-A1 | N-Substituted-5-Substituted Phthalamic Acids as Sortilin Inhibitors | H. LUNDBECK A/S (DK) | 2017-08-24 | — | — | US | disclosed |
| US-20170239226-A1 | N-Substituted-5-Substituted Phthalamic Acids as Sortilin Inhibitors | H. LUNDBECK A/S (DK) | 2017-08-24 | — | — | US | disclosed |
| US-9682967-B2 | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | H. LUNDBECK A/S (DK) | 2017-06-20 | — | — | US | disclosed |
| US-20150368231-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H. LUNDBECK A/S (DK) | 2015-12-24 | — | — | US | disclosed |
| US-20150368231-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H. LUNDBECK A/S (DK) | 2015-12-24 | — | — | US | disclosed |
| US-20150368231-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H. LUNDBECK A/S (DK) | 2015-12-24 | — | — | US | disclosed |
| EP-2948147-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H. Lundbeck A/S (DK) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014114779-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H. LUNDBECK A/S (DK) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014114779-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H. LUNDBECK A/S (DK) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368231-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | SORT1, NRP1, SELPLG | SORT1 1/4885NAMPT 958/4885SMN1; SMN2 76/4885 |
| US-10195186-B2 | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | SORT1, NRP1, SELPLG | SORT1 1/4885NAMPT 554/4885SMN1; SMN2 107/4885 |
| US-20170239226-A1 | N-Substituted-5-Substituted Phthalamic Acids as Sortilin Inhibitors | SORT1, NRP1, SELPLG | SORT1 1/4885NAMPT 554/4885SMN1; SMN2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.